Developer docs
API playgroundTry for free, no card

Search company profiles

Philochem

Full company profile

uuid0007359

Namestring
Philochem
Legal namestring
Philochem AG
Websiteurl
philochem.ch
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Philochem AG is a Swiss biotechnology company founded in 2006 and headquartered in Otelfingen, Switzerland, operating as the wholly-owned discovery research subsidiary of the Philogen group. The company focuses on innovating ligand discovery and medicinal target identification for oncology, leveraging DNA-Encoded Chemical Libraries (DELs) and self-assembling chemical library technologies to identify tumor-targeting small molecules with high affinity and selectivity. Its core platforms include OncoFAP (FAP-targeting imaging and therapeutics), OncoACP3 (Prostatic Acid Phosphatase-targeting prostate cancer radiopharmaceuticals), OncoCAIX (Carbonic Anhydrase IX-targeting renal cell carcinoma agents), Small Molecule-Drug Conjugates (SMDCs) with cytotoxic payloads such as MMAE, and immunocytokines combining tumor-targeting antibodies with cytokine payloads (IL2, TNF). These technologies are protected by patents granted in virtually all major commercial territories, including a foundational patent on production of encoded chemical libraries that was successfully defended at a Board of Appeal level in February 2024.

Philochem's pipeline is structured as theranostic pairs spanning diagnostic radionuclides (68Ga, 18F) and therapeutic radionuclides (177Lu, 225Ac), and the company conducts discovery research supporting programs in breast, esophageal, pancreatic, colorectal, prostate, and renal cancers. The company has reported Phase I clinical evidence for 68Ga-OncoFAP demonstrating safety and preliminary imaging efficacy in solid tumors. Business operations rely on a partnership-driven model: Philochem generates early-stage candidates that are either advanced internally by parent company Philogen or licensed to major pharmaceutical partners, including RayzeBio/Bristol Myers Squibb (OncoACP3, up to $1.35 billion potential value), Pfizer, Boehringer Ingelheim, Janssen, and Blue Earth Diagnostics. The company does not directly commercialize products and does not disclose standalone financial results.

The company's scientific credibility is reinforced by peer-reviewed publications in Nature Chemistry, Clinical Cancer Research, and other high-impact journals, along with industry recognition including the 2024 EFMC Prize for Young Medicinal Chemist in Industry and the 2026 Swiss Chemical Society Industrial Science Award, both awarded to Head of Research Dr. Samuele Cazzamalli. Strategic positioning centers on the Philogen/Philochem group operating model, where Philochem supplies chemistry and discovery assets and Philogen executes clinical development and commercialization, with marquee partnerships serving as both validation and monetization mechanism.

Short descriptiontext

Philochem AG is a Swiss biotech subsidiary of the Philogen group that discovers tumor-targeting ligands using DNA-Encoded Chemical Libraries and develops radiopharmaceuticals, SMDCs, and immunocytokines for cancer imaging and therapy, monetizing via partnerships and licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOtelfingen, Switzerland
HQ citystring
Otelfingen
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DNA-encoded chemical libraries, radiopharmaceutical development, cancer therapeutics discovery, small molecule drug conjugates, antibody-cytokine fusion proteins
Industry3 codes
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Oncology R&D
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1OncoFAP
Description

FAP-targeted small molecule therapeutics platform for cancer imaging and therapy

philochem.ch
+2 more records
Core offering1 text field

Philochem AG is the discovery center of the Philogen group, developing anti-cancer therapeutics and diagnostics using DNA-encoded combinatorial chemistry. It discovers and develops radiopharmaceutical imaging and therapy agents (OncoFAP, OncoACP3, OncoCAIX platforms), small molecule-drug conjugates (SMDCs) with cytotoxic payloads, and immunocytokine antibody-cytokine fusion proteins for solid tumor targeting. Pipeline candidates are advanced through licensing partnerships with pharmaceutical companies for clinical development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • $1.35 billion potential deal value from OncoACP3 licensing agreement with RayzeBio (Bristol Myers Squibb)
+1 more record
Product overview1 text field

Philochem develops anti-cancer products of unprecedented potency and selectivity using excellence in encoded combinatorial chemistry. The company operates as a Swiss subsidiary of the Philogen group, acting as the discovery center with a focus on chemical pharmaceutical products. Its portfolio includes radiopharmaceutical theranostic agents (OncoFAP and OncoACP3 series for imaging and therapy across multiple radionuclides including 68Ga, 18F, 177Lu, and 225Ac), small molecule-drug conjugates (SMDCs) with cytotoxic payloads, and immunocytokine platforms (antibody-cytokine fusion proteins). The technology foundation rests on DNA-Encoded Chemical Libraries (DEL) enabling high-throughput discovery of tumor-targeting ligands.

Product and service13 records
168Ga-OncoFAP (Imaging)
CategoryRadiopharmaceutical Imaging Agent
Description

A gallium-68 labeled radiopharmaceutical diagnostic agent for PET imaging of solid tumors, targeting Fibroblast Activation Protein (FAP). Evaluated in Phase I clinical trials in patients with breast, esophageal, pancreatic, and colorectal cancer.

218F-OncoFAP (Imaging)
CategoryRadiopharmaceutical Imaging Agent
Description

A fluorine-18 labeled radiopharmaceutical diagnostic agent for PET imaging of FAP-positive solid tumors, offering longer half-life and broader distribution logistics than gallium-68 analogs.

3177Lu-OncoFAP-23 (Therapy)
CategoryRadiopharmaceutical Therapeutic Agent
Description

A lutetium-177 labeled radiopharmaceutical therapeutic agent for targeted radionuclide therapy of FAP-expressing solid tumors.

4OncoFAP-GlyPro-MMAE (Therapy)
CategorySmall Molecule-Drug Conjugate
Description

A small molecule-drug conjugate (SMDC) that combines the OncoFAP ligand targeting Fibroblast Activation Protein with MMAE (monomethyl auristatin E) cytotoxic payload via a GlyPro linker for FAP-positive solid tumor therapy.

568Ga-OncoACP3 (Imaging)
CategoryRadiopharmaceutical Imaging Agent
Description

A gallium-68 labeled radiopharmaceutical diagnostic agent targeting Prostatic Acid Phosphatase (ACP-3) for PET imaging of prostate cancer.

618F-OncoACP3 (Imaging)
CategoryRadiopharmaceutical Imaging Agent
Description

A fluorine-18 labeled radiopharmaceutical diagnostic agent targeting ACP-3 for PET imaging of prostate cancer, offering a longer half-life alternative to gallium-68.

7177Lu-OncoACP3 (Therapy)
CategoryRadiopharmaceutical Therapeutic Agent
Description

A lutetium-177 labeled radiopharmaceutical therapeutic agent targeting ACP-3 for targeted radionuclide therapy of prostate cancer.

8225Ac-OncoACP3 (Therapy)
CategoryRadiopharmaceutical Therapeutic Agent
Description

An actinium-225 labeled radiopharmaceutical therapeutic agent targeting ACP-3 for alpha-particle therapy of prostate cancer.

968Ga-OncoCAIX (Imaging)
CategoryRadiopharmaceutical Imaging Agent
Description

A gallium-68 labeled radiopharmaceutical diagnostic agent targeting Carbonic Anhydrase IX (CAIX) for imaging renal cell carcinoma and other CAIX-expressing tumors.

10177Lu-OncoCAIX (Therapy)
CategoryRadiopharmaceutical Therapeutic Agent
Description

A lutetium-177 labeled radiopharmaceutical therapeutic agent targeting CAIX for targeted therapy of renal cell carcinoma and other CAIX-expressing tumors.

11DNA-Encoded Chemical Libraries (DEL)
CategoryDrug Discovery Technology Platform
Description

Philochem's core encoded combinatorial chemistry discovery platform enabling high-throughput identification of novel tumor-targeting ligands, including patented DNA-encoded self-assembling chemical library technology. Offered as a discovery platform accessible through partnering and fee-for-service engagements.

12Immunocytokines
CategoryTherapeutic Platform
Description

Therapeutic platform of antibody-cytokine fusion proteins (e.g., L19IL2, L19TNF, F8-IL10/Dekavil) that combine tumor-targeting antibodies with cytokine payloads (IL2, TNF, IL10) for cancer therapy and chronic inflammation treatment.

13Small Molecule-Drug Conjugates (SMDCs)
CategoryTherapeutic Platform
Description

Non-internalizing small molecule-drug conjugate platform delivering cytotoxic payloads (e.g., MMAE, camptothecin derivatives) to tumors via FAP targeting for solid tumor therapy.

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-10
Description

Philochem AG licensed worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio (a Bristol Myers Squibb company). The deal closed on August 18, 2025 following antitrust clearance, with potential value of up to $1.35 billion plus royalties.

2Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-10-12
Description

Philogen signed a collaborative agreement with Boehringer Ingelheim to investigate novel treatment approaches for Acute Myeloid Leukemia using DNA-encoded chemistry.

philochem.ch
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-12-22
Description

Philogen announced Option and License Agreement with Pfizer Inc. to develop and commercialize multiple antibody drug conjugates and targeted nanoparticles.

Strategic tierCoreTypeOthers
Description

Philochem is a Swiss subsidiary of the Philogen group, acting as the discovery center with a focus on chemical pharmaceutical products and technologies. Philogen handles clinical development and commercialization of Philochem's discoveries.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for Phase 1 clinical trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for diagnostic imaging in solid tumors. First three patients imaged in the clinical trial.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Philogen announced new collaboration with Janssen to discover small molecule therapeutics, expanding the partnership portfolio in the pharmaceutical sector.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Parent company of Philochem and co-developer of the antibody-cytokine (immunocytokine) and SMDC pipeline. Operates the clinical development and commercialization arm for Philochem's discoveries, making it the most direct functional peer in the same therapeutic programs and target classes.

TypeBroad incumbent
Description

Approved Pluvicto (Lu-177 vipivotide tetraxetan), the first commercial PSMA-directed radioligand therapy, and runs parallel FAP and radioligand discovery programs through its oncology and radioligand therapy units. Sets the efficacy, safety, and commercial benchmark against which Philochem's OncoACP3, OncoFAP, and OncoCAIX programs will be measured.

TypeDirect peer
Description

Radiopharmaceutical company with established diagnostic imaging agents (e.g., PYLARIFY, AZEDRA) and an active radioligand therapy pipeline including FAP and PSMA-targeted programs. Direct competitor in both imaging diagnostics and radionuclide therapy for solid tumors.

TypeDirect peer
Description

Commercial-stage radiopharmaceutical company with PSMA-PET imaging (Illuccix) and a pipeline of CAIX- and FAP-targeted agents. Direct overlap with Philochem's OncoCAIX and OncoFAP programs across imaging and therapeutic radionuclides.

TypeBroad incumbent
Description

Develops and markets radiopharmaceuticals (e.g., Xofigo, Nubeqa) and runs an active pipeline in FAP- and PSMA-targeted radionuclide therapy. Overlaps directly with Philochem's radioligand therapy programs across prostate cancer and solid tumors.

TypeDirect peer
Description

Vertically integrated radiopharmaceutical company supplying diagnostic and therapeutic nuclear medicine products globally. Competes in the same theranostic oncology space, particularly in PET imaging agents and emerging Lu-177 therapies.

TypeDirect peer
Description

BMS-owned radiopharmaceutical company that licensed OncoACP3 from Philochem for up to $1.35B. Now both Philochem's most important commercial partner and a direct competitor advancing internal actinium-225 and lutetium-based radioligand programs in oncology.

TypeEmerging player
Description

Develops bicyclic peptide-based targeted therapeutics including Bicycle Toxin Conjugates, which share conceptual overlap with Philochem's SMDCs (targeted small-molecule cytotoxics). Comparable emerging modality in the targeted oncology conjugates space.

TypeRegional player
Description

Italian-headquartered diagnostic imaging company with a portfolio of contrast agents and radiopharmaceuticals for oncology imaging. Overlaps with Philochem's PET imaging diagnostic agents (68Ga/18F-OncoFAP, OncoACP3, OncoCAIX) in the European market.

TypeEmerging player
Description

Swiss clinical-stage biotech developing DARPin-based targeted therapeutics for oncology, with comparable company size and Swiss biotech operating model. Peer through similar discovery-platform approach to oncology targeting, though using protein scaffolds rather than DELs.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Philochem

Biopharmaceutical Oncology R&Dphilochem.ch

Philochem AG is a Swiss biotech subsidiary of the Philogen group that discovers tumor-targeting ligands using DNA-Encoded Chemical Libraries and develops radiopharmaceuticals, SMDCs, and immunocytokines for cancer imaging and therapy, monetizing via partnerships and licensing.

What Philochem does

Philochem AG is a Swiss biotechnology company founded in 2006 and headquartered in Otelfingen, Switzerland, operating as the wholly-owned discovery research subsidiary of the Philogen group. The company focuses on innovating ligand discovery and medicinal target identification for oncology, leveraging DNA-Encoded Chemical Libraries (DELs) and self-assembling chemical library technologies to identify tumor-targeting small molecules with high affinity and selectivity. Its core platforms include OncoFAP (FAP-targeting imaging and therapeutics), OncoACP3 (Prostatic Acid Phosphatase-targeting prostate cancer radiopharmaceuticals), OncoCAIX (Carbonic Anhydrase IX-targeting renal cell carcinoma agents), Small Molecule-Drug Conjugates (SMDCs) with cytotoxic payloads such as MMAE, and immunocytokines combining tumor-targeting antibodies with cytokine payloads (IL2, TNF). These technologies are protected by patents granted in virtually all major commercial territories, including a foundational patent on production of encoded chemical libraries that was successfully defended at a Board of Appeal level in February 2024.

Philochem's pipeline is structured as theranostic pairs spanning diagnostic radionuclides (68Ga, 18F) and therapeutic radionuclides (177Lu, 225Ac), and the company conducts discovery research supporting programs in breast, esophageal, pancreatic, colorectal, prostate, and renal cancers. The company has reported Phase I clinical evidence for 68Ga-OncoFAP demonstrating safety and preliminary imaging efficacy in solid tumors. Business operations rely on a partnership-driven model: Philochem generates early-stage candidates that are either advanced internally by parent company Philogen or licensed to major pharmaceutical partners, including RayzeBio/Bristol Myers Squibb (OncoACP3, up to $1.35 billion potential value), Pfizer, Boehringer Ingelheim, Janssen, and Blue Earth Diagnostics. The company does not directly commercialize products and does not disclose standalone financial results.

The company's scientific credibility is reinforced by peer-reviewed publications in Nature Chemistry, Clinical Cancer Research, and other high-impact journals, along with industry recognition including the 2024 EFMC Prize for Young Medicinal Chemist in Industry and the 2026 Swiss Chemical Society Industrial Science Award, both awarded to Head of Research Dr. Samuele Cazzamalli. Strategic positioning centers on the Philogen/Philochem group operating model, where Philochem supplies chemistry and discovery assets and Philogen executes clinical development and commercialization, with marquee partnerships serving as both validation and monetization mechanism.

Philochem firmographics

Firmographics
Name
Philochem
Legal name
Philochem AG
Website
https://philochem.ch
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
Philochem AG is a Swiss biotech subsidiary of the Philogen group that discovers tumor-targeting ligands using DNA-Encoded Chemical Libraries and develops radiopharmaceuticals, SMDCs, and immunocytokines for cancer imaging and therapy, monetizing via partnerships and licensing.
Ownership category
akta.pro rank

Philochem industry classification

Industry
Product category
Biopharmaceutical Oncology R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • DNA-encoded chemical libraries
  • Radiopharmaceutical development
  • Cancer therapeutics discovery
  • Small molecule drug conjugates
  • Antibody-cytokine fusion proteins

Where Philochem is headquartered

Location

Headquarters

HQ city
Otelfingen
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Philochem business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Philochem product offering

Product offering

Core offering

Philochem AG is the discovery center of the Philogen group, developing anti-cancer therapeutics and diagnostics using DNA-encoded combinatorial chemistry. It discovers and develops radiopharmaceutical imaging and therapy agents (OncoFAP, OncoACP3, OncoCAIX platforms), small molecule-drug conjugates (SMDCs) with cytotoxic payloads, and immunocytokine antibody-cytokine fusion proteins for solid tumor targeting. Pipeline candidates are advanced through licensing partnerships with pharmaceutical companies for clinical development and commercialization.

Product overview

Philochem develops anti-cancer products of unprecedented potency and selectivity using excellence in encoded combinatorial chemistry. The company operates as a Swiss subsidiary of the Philogen group, acting as the discovery center with a focus on chemical pharmaceutical products. Its portfolio includes radiopharmaceutical theranostic agents (OncoFAP and OncoACP3 series for imaging and therapy across multiple radionuclides including 68Ga, 18F, 177Lu, and 225Ac), small molecule-drug conjugates (SMDCs) with cytotoxic payloads, and immunocytokine platforms (antibody-cytokine fusion proteins). The technology foundation rests on DNA-Encoded Chemical Libraries (DEL) enabling high-throughput discovery of tumor-targeting ligands.

Differentiator

Problem solved

Functional benefit

Brands

  • OncoFAP: FAP-targeted small molecule therapeutics platform for cancer imaging and therapy
  • OncoACP3
  • OncoCAIX

Products and services

  • 68Ga-OncoFAP (Imaging) A gallium-68 labeled radiopharmaceutical diagnostic agent for PET imaging of solid tumors, targeting Fibroblast Activation Protein (FAP). Evaluated in Phase I clinical trials in patients with breast, esophageal, pancreatic, and colorectal cancer.
  • 18F-OncoFAP (Imaging) A fluorine-18 labeled radiopharmaceutical diagnostic agent for PET imaging of FAP-positive solid tumors, offering longer half-life and broader distribution logistics than gallium-68 analogs.
  • 177Lu-OncoFAP-23 (Therapy) A lutetium-177 labeled radiopharmaceutical therapeutic agent for targeted radionuclide therapy of FAP-expressing solid tumors.
  • OncoFAP-GlyPro-MMAE (Therapy) A small molecule-drug conjugate (SMDC) that combines the OncoFAP ligand targeting Fibroblast Activation Protein with MMAE (monomethyl auristatin E) cytotoxic payload via a GlyPro linker for FAP-positive solid tumor therapy.
  • 68Ga-OncoACP3 (Imaging) A gallium-68 labeled radiopharmaceutical diagnostic agent targeting Prostatic Acid Phosphatase (ACP-3) for PET imaging of prostate cancer.
  • 18F-OncoACP3 (Imaging) A fluorine-18 labeled radiopharmaceutical diagnostic agent targeting ACP-3 for PET imaging of prostate cancer, offering a longer half-life alternative to gallium-68.
  • 177Lu-OncoACP3 (Therapy) A lutetium-177 labeled radiopharmaceutical therapeutic agent targeting ACP-3 for targeted radionuclide therapy of prostate cancer.
  • 225Ac-OncoACP3 (Therapy) An actinium-225 labeled radiopharmaceutical therapeutic agent targeting ACP-3 for alpha-particle therapy of prostate cancer.
  • 68Ga-OncoCAIX (Imaging) A gallium-68 labeled radiopharmaceutical diagnostic agent targeting Carbonic Anhydrase IX (CAIX) for imaging renal cell carcinoma and other CAIX-expressing tumors.
  • 177Lu-OncoCAIX (Therapy) A lutetium-177 labeled radiopharmaceutical therapeutic agent targeting CAIX for targeted therapy of renal cell carcinoma and other CAIX-expressing tumors.
  • DNA-Encoded Chemical Libraries (DEL) Philochem's core encoded combinatorial chemistry discovery platform enabling high-throughput identification of novel tumor-targeting ligands, including patented DNA-encoded self-assembling chemical library technology. Offered as a discovery platform accessible through partnering and fee-for-service engagements.
  • Immunocytokines Therapeutic platform of antibody-cytokine fusion proteins (e.g., L19IL2, L19TNF, F8-IL10/Dekavil) that combine tumor-targeting antibodies with cytokine payloads (IL2, TNF, IL10) for cancer therapy and chronic inflammation treatment.
  • Small Molecule-Drug Conjugates (SMDCs) Non-internalizing small molecule-drug conjugate platform delivering cytotoxic payloads (e.g., MMAE, camptothecin derivatives) to tumors via FAP targeting for solid tumor therapy.

Quantifiable outcome

  • $1.35 billion potential deal value from OncoACP3 licensing agreement with RayzeBio (Bristol Myers Squibb)
  • +1 more outcomes

Companies that use Philochem

Customer profile

Segments1 record

Ideal customer profiles1 record

Philochem technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Philochem partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship and core.

  • RayzeBio, a Bristol Myers Squibb CompanyflagshipStrategic or Co-development Partner · 10 June 2025Philochem AG licensed worldwide rights to OncoACP3, a novel radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio (a Bristol Myers Squibb company). The deal closed on August 18, 2025 following antitrust clearance, with potential value of up to $1.35 billion plus royalties.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 12 October 2015Philogen signed a collaborative agreement with Boehringer Ingelheim to investigate novel treatment approaches for Acute Myeloid Leukemia using DNA-encoded chemistry.
  • Pfizer Inc.coreStrategic or Co-development Partner · 22 December 2014Philogen announced Option and License Agreement with Pfizer Inc. to develop and commercialize multiple antibody drug conjugates and targeted nanoparticles.
  • PhilogencoreOthersPhilochem is a Swiss subsidiary of the Philogen group, acting as the discovery center with a focus on chemical pharmaceutical products and technologies. Philogen handles clinical development and commercialization of Philochem's discoveries.
  • Blue Earth DiagnosticscoreStrategic or Co-development PartnerCollaboration for Phase 1 clinical trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for diagnostic imaging in solid tumors. First three patients imaged in the clinical trial.
  • Janssen (Johnson & Johnson)coreStrategic or Co-development PartnerPhilogen announced new collaboration with Janssen to discover small molecule therapeutics, expanding the partnership portfolio in the pharmaceutical sector.

Recent moves6 records

Expansion highlights6 records

Philochem competitors and assessment

Company assessment

Direct peers

  • Philogen S.p.A. Parent company of Philochem and co-developer of the antibody-cytokine (immunocytokine) and SMDC pipeline. Operates the clinical development and commercialization arm for Philochem's discoveries, making it the most direct functional peer in the same therapeutic programs and target classes.
  • Lantheus Holdings: Radiopharmaceutical company with established diagnostic imaging agents (e.g., PYLARIFY, AZEDRA) and an active radioligand therapy pipeline including FAP and PSMA-targeted programs. Direct competitor in both imaging diagnostics and radionuclide therapy for solid tumors.
  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with PSMA-PET imaging (Illuccix) and a pipeline of CAIX- and FAP-targeted agents. Direct overlap with Philochem's OncoCAIX and OncoFAP programs across imaging and therapeutic radionuclides.
  • Curium: Vertically integrated radiopharmaceutical company supplying diagnostic and therapeutic nuclear medicine products globally. Competes in the same theranostic oncology space, particularly in PET imaging agents and emerging Lu-177 therapies.
  • RayzeBio (Bristol Myers Squibb): BMS-owned radiopharmaceutical company that licensed OncoACP3 from Philochem for up to $1.35B. Now both Philochem's most important commercial partner and a direct competitor advancing internal actinium-225 and lutetium-based radioligand programs in oncology.

Broad incumbents

  • Novartis (Pluvicto): Approved Pluvicto (Lu-177 vipivotide tetraxetan), the first commercial PSMA-directed radioligand therapy, and runs parallel FAP and radioligand discovery programs through its oncology and radioligand therapy units. Sets the efficacy, safety, and commercial benchmark against which Philochem's OncoACP3, OncoFAP, and OncoCAIX programs will be measured.
  • Bayer (Radiopharmaceuticals): Develops and markets radiopharmaceuticals (e.g., Xofigo, Nubeqa) and runs an active pipeline in FAP- and PSMA-targeted radionuclide therapy. Overlaps directly with Philochem's radioligand therapy programs across prostate cancer and solid tumors.

Emerging players

  • Bicycle Therapeutics: Develops bicyclic peptide-based targeted therapeutics including Bicycle Toxin Conjugates, which share conceptual overlap with Philochem's SMDCs (targeted small-molecule cytotoxics). Comparable emerging modality in the targeted oncology conjugates space.
  • Molecular Partners: Swiss clinical-stage biotech developing DARPin-based targeted therapeutics for oncology, with comparable company size and Swiss biotech operating model. Peer through similar discovery-platform approach to oncology targeting, though using protein scaffolds rather than DELs.

Regional players

  • Bracco Imaging: Italian-headquartered diagnostic imaging company with a portfolio of contrast agents and radiopharmaceuticals for oncology imaging. Overlaps with Philochem's PET imaging diagnostic agents (68Ga/18F-OncoFAP, OncoACP3, OncoCAIX) in the European market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Philochem social profiles

Digital presence

Philochem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Philochem leadership team

Management profile

Number of profiles

Profiles9 records

Philochem funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Philochem M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Philochem

What does Philochem do?

Philochem AG is the discovery center of the Philogen group, developing anti-cancer therapeutics and diagnostics using DNA-encoded combinatorial chemistry. It discovers and develops radiopharmaceutical imaging and therapy agents (OncoFAP, OncoACP3, OncoCAIX platforms), small molecule-drug conjugates (SMDCs) with cytotoxic payloads, and immunocytokine antibody-cytokine fusion proteins for solid tumor targeting. Pipeline candidates are advanced through licensing partnerships with pharmaceutical companies for clinical development and commercialization.

Is Philochem a public or private company?

Philochem is a private company. It is classified as corporate owned and is currently operating.

When was Philochem founded?

Philochem was founded in 2006. It employs 51 to 100 people.

Where is Philochem based?

Philochem is headquartered in Otelfingen, Switzerland, in the Europe region.

Who are Philochem's main competitors?

Direct peers on record are Philogen S.p.A., Lantheus Holdings, Telix Pharmaceuticals, Curium and RayzeBio (Bristol Myers Squibb). Broad incumbents are Novartis (Pluvicto) and Bayer (Radiopharmaceuticals). Emerging players are Bicycle Therapeutics and Molecular Partners. Bracco Imaging is listed as a regional player.

Does Philochem have an API?

No public API is recorded for Philochem.

What industry is Philochem in?

Philochem's product category is Biopharmaceutical Oncology R&D. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswirePhilochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb CompanPhilochem AG licensed worldwide rights to OncoACP3, a prostate cancer radiopharmaceutical, to RayzeBio, a Bristol-Myers Squibb subsidiary. The deal includes a $350m up-front payment and up to $1bn in milestones, with closing expected in Q3 2025.GlobeNewswirePhilochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb CompanPhilochem AG licensed worldwide rights to OncoACP3, a prostate cancer radiopharmaceutical, to RayzeBio, a Bristol-Myers Squibb subsidiary. The deal includes a $350m up-front payment and up to $1bn in milestones, with closing expected in Q3 2025.GlobeNewswirePhilochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid TumorsPhilochem and Blue Earth Diagnostics announced the first three patients were imaged in a Phase 1 trial of 68Ga-OncoFAP for solid tumors. The trial, planned to enroll up to 20 patients, is underway in Europe. Blue Earth Diagnostics will assume further clinical development and commercialization worldwide.BioSpacePhilochem AG, Seibersdorf Labor GmbH and Isotopia announce supply, development, and manufacturing agreementsPhilochem, Seibersdorf Laboratories, and Isotopia Molecular Imaging signed agreements to advance radiopharmaceutical cancer therapies. Isotopia will supply 177Lu-n.c.a. to Seibersdorf for developing and manufacturing Philochem's OncoFAP-23, a targeted radionuclide therapy. The collaboration aims to bring the product to clinical development.PR NewswirePhilochem AG, Seibersdorf Labor GmbH and Isotopia announce supply, development, and manufacturing agreementsPhilochem, Seibersdorf Laboratories, and Isotopia Molecular Imaging have signed a three-way agreement to advance the development of radiopharmaceutical therapies for cancer treatment, with Isotopia supplying 177Lutetium N.C.A. to Seibersdorf for manufacturing Philochem's therapeutic candidate OncoFAP-23. The collaboration aims to support Philochem's bench-to-bedside translational research on 177Lu-OncoFAP-23, a novel small molecule ligand targeting Fibroblast Activation Protein (FAP) expressed in solid malignancies. Isotopia's GMP-produced 177Lu n.c.a. offers high purity without Mercury or metastable 177Lu-m, enabling precise tumor-targeting radionuclide therapy in precision medicine oncology.GlobeNewswirePhilochem and Bracco Imaging Announce a Collaboration on the Development of a Small Molecule for Diagnostic or Medical Imaging ApplicationsPhilochem and Bracco Imaging announced a license and collaboration agreement to develop and commercialize a small organic molecule for imaging applications. The molecule is designed to selectively detect metastatic solid tumors in cancer patients, aiming to improve diagnosis and monitoring. Both companies are committed to making the product available to patients.GlobeNewswirePHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICSPhilogen's Swiss subsidiary Philochem AG entered a collaboration and option agreement with Janssen Biotech to discover small molecules using Philochem's DNA-encoded chemical library technology. Janssen may exercise options to develop identified ligands, but no financial terms were disclosed.PR NewswirePhilogen Announces Option Exercise by JanssenPhilogen S.p.A. announced that Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has exercised an option under their drug discovery collaboration to identify new small molecule-based therapeutics using Philochem AG's novel lead-generation technologies. The original collaboration was announced in January 2019 and was facilitated by Johnson & Johnson Innovation LLC. No financial details of the agreement were disclosed.